Table 3.
Spending and utilization market shares of individual ICIs over time, 2011–21
| Year | Ipilimumab | Pembrolizumab | Nivolumab | Atezolizumab | Avelumab | Cemiplimab | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spending (%) | Utilization (%) | Spending (%) | Utilization (%) | Spending (%) | Utilization (%) | Spending (%) | Utilization (%) | Spending (%) | Utilization (%) | Spending (%) | Utilization (%) | |
| 2011 | 100.0 | 100.0 | – | – | – | – | – | – | – | – | – | – |
| 2012 | 100.0 | 100.0 | – | – | – | – | – | – | – | – | – | – |
| 2013 | 100.0 | 100.0 | – | – | – | – | – | – | – | – | – | – |
| 2014 | 99.3 | 97.8 | 0.7 | 2.2 | – | – | – | – | – | – | – | – |
| 2015 | 55.7 | 16.9 | 5.4 | 5.5 | 38.9 | 77.7 | – | – | – | – | – | – |
| 2016 | 11.0 | 1.8 | 4.8 | 3.6 | 83.9 | 94.4 | 0.3 | 0.2 | – | – | – | – |
| 2017 | 9.7 | 1.4 | 15.9 | 11.3 | 72.9 | 86.2 | 1.6 | 1.2 | – | – | – | – |
| 2018 | 8.8 | 2.7 | 36.9 | 29.0 | 50.7 | 65.3 | 3.5 | 2.8 | 0.1 | 0.2 | – | – |
| 2019 | 7.0 | 3.2 | 46.5 | 43.3 | 37.5 | 44.8 | 8.8 | 8.3 | 0.1 | 0.2 | 0.2 | 0.2 |
| 2020 | 5.4 | 2.8 | 50.8 | 47.4 | 39.2 | 44.8 | 4.1 | 4.3 | 0.1 | 0.2 | 0.4 | 0.5 |
| 2021 | 7.1 | 4.4 | 60.0 | 57.0 | 20.8 | 25.8 | 11.0 | 11.2 | 0.4 | 0.7 | 0.7 | 0.9 |
Ipilimumab dominated the market as the sole ICI until 2014. After 2014, pembrolizumab and nivolumab have dominated the ICI market. Pembrolizumab had the greatest market share among the ICIs included in the study by 2021, claiming over 40% of the market in both spending and utilization
ICI immune checkpoint inhibitors